Tags: Amyvid™

blog

April 16, 2019

PET Scans Improve Management of Patients with Dementia

A national study has found that PET scans significantly influenced clinical management of patients with dementia.

blog

August 2, 2018

Top Five Highlights from AAIC 2018

The ADDF looks back at the 2018 Alzheimer's Association International Conference.

blog

December 28, 2017

Alzheimer’s Biomarkers, Explained

Learn what a biomarker is, why they matter to the ADDF, which biomarkers we have, and which ones we need.  

blog

March 6, 2017

Prevention: A Key to Conquering Alzheimer’s

Dr. Howard Fillit explains the importance of prevention to the ADDF's mission and our current efforts, including clinical trials. 

blog

November 25, 2016

What Does the Failure of Solanezumab Mean?

Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means, and where we go from here.

blog

September 2, 2016

ADDF-Funded PET Imaging Makes Clinical Trial Success Possible

A treatment has reduced beta-amyloid plaques in the brains of patients with Alzheimer’s disease. 

blog

February 25, 2016

Alzheimer’s Drug Featured in Time Was Made Possible by the ADDF

Grantee Dr. Frank Longo's promising new drug to treat Alzheimer's is on the cover of Time magazine.

blog

June 10, 2015

Investing in a Cure

Investing more in drug discovery and development is the best chance we have for finding a cure for Alzheimer's disease.

blog

August 19, 2013

The Balancing Act of Healthcare Reform

I recently saw a patient who was afraid he had Alzheimer's disease. A new scan made it easy to give him an accurate diagnosis. So why can't most patients use it? 

blog

June 4, 2013

Fighting Alzheimer’s Costs Now & in the Future

The current costs of dementia care are enormous. But the future costs could create a crippling financial burden on our society, as the number of people diagnosed with dementia is expected to more than double in the next 30 years.

announcements

February 5, 2013

Medicare Panel’s Failure to Recommend Payment for New Alzheimer’s Diagnostic Brain Imaging Scans

Howard Fillit, MD and George Vradenburg of USAgainstAlzheimer's issued a joint statement, responding to MEDCAC's opinion to not support Medicare reimbursement for PET amyloid imaging scans.

announcements

April 6, 2012

ADDF’s Seed Funding Leads to FDA Approval of Amyvid™, First Diagnostic Test for Alzheimer’s Disease

The FDA has approved Amyvid™, the first diagnostic test for Alzheimer's disease, for which the ADDF provided critical seed funding.